Related references
Note: Only part of the references are listed.The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
Jiajun Liu et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Is There a Difference Between Minimal and Gross Extension into the Strap Muscles for the Risk of Recurrence in Papillary Thyroid Carcinomas?
Debora L. S. Danilovic et al.
THYROID (2020)
Evaluation of Parotid Salivary Gland Echo Texture by Ultrasound Examinations and Correlation With Whole-Body Scintigraphy After Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma
Graziele Aparecida Simoes Lima et al.
JOURNAL OF ULTRASOUND IN MEDICINE (2020)
Molecular profile of Hurthle cell carcinomas: recurrent mutations in the Wnt/β-caten n pathway
Nathalie Oliveira Santana et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors
Wei Zheng et al.
NUCLEAR MEDICINE COMMUNICATIONS (2019)
Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management
Hong Song et al.
CLINICAL NUCLEAR MEDICINE (2018)
Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?
R. Michael Tuttle et al.
THYROID (2017)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen et al.
THYROID (2016)
Preablation 131-I Scans With SPECT/CT Contribute to Thyroid Cancer Risk Stratification and 131-I Therapy Planning
Anca M. Avram et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyrotropin on Glomerular Filtration Rate During Radioiodine Therapy for Well-Differentiated Thyroid Cancer
George Barberio Coura-Filho et al.
THYROID (2015)
No Adverse Affect in Clinical Outcome Using Low Preablation Diagnostic 131I Activity in Differentiated Thyroid Cancer: Refuting Thyroid-Stunning Effect
Beng Khiong Yap et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Focus on High-Risk DTC Patients High Postoperative Serum Thyroglobulin Level Is a Strong Predictor of Disease Persistence and Is Associated to Progression-Free Survival and Overall Survival
Arnoldo Piccardo et al.
CLINICAL NUCLEAR MEDICINE (2013)
A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients
Eyal Robenshtok et al.
THYROID (2013)
Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients
Hadiza S. Kazaure et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans
Eun-Kyung Park et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
The success of I-131 ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq I-131
F. A. Verburg et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2009)
Review: I-131 activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review
Allan Hackshaw et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Outcomes of patients with differentiated thyroid carcinoma following initial therapy
Jacqueline Jonklaas et al.
THYROID (2006)
Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma
TY Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma:: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation
YH Hu et al.
NUCLEAR MEDICINE COMMUNICATIONS (2004)
Predictive value of serum thyroglobulin after surgery for thyroid carcinoma
FT Hall et al.
LARYNGOSCOPE (2003)
Share Paper
